- Stackpole, Mary L;
- Zeng, Weihua;
- Li, Shuo;
- Liu, Chun-Chi;
- Zhou, Yonggang;
- He, Shanshan;
- Yeh, Angela;
- Wang, Ziye;
- Sun, Fengzhu;
- Li, Qingjiao;
- Yuan, Zuyang;
- Yildirim, Asli;
- Chen, Pin-Jung;
- Winograd, Paul;
- Tran, Benjamin;
- Lee, Yi-Te;
- Li, Paul Shize;
- Noor, Zorawar;
- Yokomizo, Megumi;
- Ahuja, Preeti;
- Zhu, Yazhen;
- Tseng, Hsian-Rong;
- Tomlinson, James S;
- Garon, Edward;
- French, Samuel;
- Magyar, Clara E;
- Dry, Sarah;
- Lajonchere, Clara;
- Geschwind, Daniel;
- Choi, Gina;
- Saab, Sammy;
- Alber, Frank;
- Wong, Wing Hung;
- Dubinett, Steven M;
- Aberle, Denise R;
- Agopian, Vatche;
- Han, Steven-Huy B;
- Ni, Xiaohui;
- Li, Wenyuan;
- Zhou, Xianghong Jasmine
Early cancer detection by cell-free DNA faces multiple challenges: low fraction of tumor cell-free DNA, molecular heterogeneity of cancer, and sample sizes that are not sufficient to reflect diverse patient populations. Here, we develop a cancer detection approach to address these challenges. It consists of an assay, cfMethyl-Seq, for cost-effective sequencing of the cell-free DNA methylome (with > 12-fold enrichment over whole genome bisulfite sequencing in CpG islands), and a computational method to extract methylation information and diagnose patients. Applying our approach to 408 colon, liver, lung, and stomach cancer patients and controls, at 97.9% specificity we achieve 80.7% and 74.5% sensitivity in detecting all-stage and early-stage cancer, and 89.1% and 85.0% accuracy for locating tissue-of-origin of all-stage and early-stage cancer, respectively. Our approach cost-effectively retains methylome profiles of cancer abnormalities, allowing us to learn new features and expand to other cancer types as training cohorts grow.